Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open label study of the effect of daily treatment with MPC-7869 in subjects with dementia of the Alzheimer's type.

Next Previous
Search
Trial Profile

Open label study of the effect of daily treatment with MPC-7869 in subjects with dementia of the Alzheimer's type.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 Nov 2012

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tarenflurbil (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Registrational

Most Recent Events

  • 28 Apr 2012 Planned number of patients changed from 1000 to 1661 as reported by European Clinical Trials Database.
  • 01 Aug 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
  • 09 May 2007 New trial record.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top